Peer-Reviewed Publication
Am J Cardiovasc Drugs2025;25(6):829-839.November 1, 2025Clinical Trial, Phase III
Contemporary Oral Medication Use and Frequency in Patients with Transthyretin Amyloid Cardiomyopathy.
Noel Dasgupta1, Steen Hvitfeldt Poulsen2, Michele Emdin3, Amrut V Ambardekar4, Keyur B Shah5, Liana Hennum6, Rohit Marwah7, Melissa Allison7, Pruthviraj Shivanna7, Suresh Siddhanti6, Jean-François Tamby6, Heather Falvey6, Justin L Grodin8
1Indiana University School of Medicine, Indianapolis, IN, USA.
2Department of Cardiology, Aarhus University, Aarhus, Denmark.
3Scuola Superiore Sant'Anna and Fondazione G. Monasterio, Pisa, Italy.
4University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
5Virginia Commonwealth University Health, Richmond, VA, USA.
6BridgeBio Pharma Inc., San Francisco, CA, USA.
7Definitive Healthcare Group, Framingham, MA, USA.
8University of Texas Southwestern, Dallas, TX, USA. justin.grodin@utsouthwestern.edu.
Abstract
INTRODUCTION: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure (HF), with a higher prevalence in older patients with comorbidities requiring concomitant medical therapy. Acoramidis is a next-generation transthyretin stabilizer with near-complete protein stabilization (≥ 90%) administered orally twice daily (BID) for treatment of ATTR-CM. We report…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans